Chronic Venous Occlusions Treatment Market Forecast 2026-2036: Market to Reach USD 17.84 Billion by 2036 at 6.4% CAGR

NEWARK, DE | The chronic venous occlusions treatment market stood at USD 9.0 billion in 2025. According to Future Market Insights analysis, the market is projected to expand to USD 9.58 billion in 2026 and reach USD 17.84 billion by 2036, registering a steady CAGR of 6.4% over the 2026-2036 forecast period. This expansion is powered by the widespread transition from traditional open surgical methods to minimally invasive endovenous procedures, combination therapies, and advanced device platforms that target both the occlusion and its underlying causes while significantly lowering patient morbidity and recovery time.

Read Full Report:https://www.futuremarketinsights.com/reports/chronic-venous-occlusions-treatment-market

Market snapshot: global market 2026 - 2036

Market size 2026? USD 9.58 billion
Market size 2036? USD 17.84 billion
CAGR? 6.4%
Leading treatment type segment and share: Endovenous laser ablation 32.6%
Leading product segment and share: Devices 52.9%
Leading end user segment and share: Hospitals 45.2%
Key growth regions: Asia Pacific (fastest expansion through infrastructure development and awareness); North America (largest revenue share via high procedure volumes and reimbursement support)
Top companies: Cardinal Health, Stryker, Boston Scientific Corporation, Edwards Lifesciences, Cook Medical, Medtronic, AngioDynamics, Gore, Bayer AG, Sanofi
The chronic venous occlusions treatment market follows a consistent upward trajectory: from USD 9.0 billion in 2025 to USD 9.58 billion in 2026, continuing through gradual yearly gains driven by procedure migration and technology adoption, ultimately delivering an absolute dollar increase of USD 8.26 billion between 2026 and 2036 to arrive at USD 17.84 billion by the end of the forecast horizon.

Why the Market is Growing

An aging global population is fueling higher incidence of venous disease, with people aged 65+ forming the fastest-growing group receiving venous interventions. Greater adoption of minimally invasive endovenous approaches delivers quicker recovery, fewer complications, and strong suitability for ambulatory and office-based delivery. Heightened awareness of the serious downstream effects of untreated chronic venous disease-including venous ulcers, elevated pulmonary embolism risk, and diminished quality of life-is converting previously undertreated patients into active candidates for intervention.

Segment Spotlight

Treatment Type

Endovenous laser ablation commands 32.6% of the chronic venous occlusions treatment market in 2025, anchored by robust clinical evidence, widespread reimbursement approval, and compatibility with office-based settings that avoid general anesthesia. The technique consistently achieves occlusion rates above 95% with low complication profiles, making it the benchmark for newer modalities. Systems have progressed from fixed-wavelength platforms to adaptive wavelength optimization tailored to vein diameter and depth, now frequently featuring automated pullback for standardized energy delivery and reduced operator variability.

Product

Devices hold 52.9% share in the chronic venous occlusions treatment market, underscoring the technology-driven character of contemporary venous care and the recurring revenue generated by single-use components. Dedicated venous stents-engineered for larger diameters, lower pressure environments, and enhanced flexibility-have largely supplanted repurposed arterial devices. Innovation frontiers include drug-eluting balloons and stents aimed at lowering restenosis, alongside optimized mechanical thrombectomy tools that reduce post-thrombotic syndrome risk. Intravascular ultrasound (IVUS) has become standard in complex cases, offering precise lesion assessment and deployment verification unavailable through conventional venography.

End Use

Hospitals currently capture 45.2% of procedures in the chronic venous occlusions treatment market, reflecting their historical role in managing complex vascular cases. However, ambulatory surgical centers are the fastest-growing channel as procedures rapidly shift outpatient. The migration yields 30-50% cost reductions alongside improved patient experience and scheduling flexibility. Office-based labs and dedicated vein centers staffed by phlebologists and vascular specialists are proliferating, while over 58% of facilities now operate integrated shared-care models that coordinate interventional, radiologic, and follow-up services across settings for greater efficiency.

Drivers, Opportunities, Trends, Challenges

Drivers

The chronic venous occlusions treatment market benefits from rising disease recognition and prevalence-over 30 million Americans live with some form of chronic venous disease, roughly ten times more common than peripheral artery disease. A projected 13% global increase in the population aged 65+ by 2035 directly amplifies demand. The paradigm shift to minimally invasive techniques has broadened the treatable population by offering options acceptable to patients who previously avoided invasive surgery.

Opportunities

Manufacturers can capture value by developing venous-specific stent platforms optimized for venous hemodynamics rather than adapting arterial designs. Physician training initiatives that facilitate the move to office-based and ambulatory settings will cultivate long-term loyalty among emerging interventionalists. Pipelines that combine mechanical thrombectomy with localized pharmacologic delivery present strong potential to mitigate post-thrombotic syndrome and improve long-term patency.

Trends

Endovenous methods now dominate venous interventions, fundamentally expanding market reach. Over 59% of procedures incorporate advanced digital imaging and precision guidance. Personalized treatment decisions-guided by detailed imaging analytics and patient-specific variables-influence more than 60% of cases, laying groundwork for increasingly tailored protocols.

Challenges

Historically, the chronic venous occlusions treatment market was constrained by the invasiveness of open surgery, extended recovery, and patient aversion to operative risk, limiting overall scale. Even with high disease prevalence, treatment penetration remains comparatively low due to lingering awareness gaps and access barriers in certain regions.

Competitive Landscape

The chronic venous occlusions treatment market remains moderately consolidated. Boston Scientific Corporation, Medtronic, and Cardinal Health hold leading positions across several categories. Stryker excels in thrombectomy solutions, while Cook Medical maintains a robust venous stent offering. Edwards Lifesciences continues expanding from surgical into endovascular applications. Additional notable players include AngioDynamics, Gore, Bayer AG, and Sanofi. Strategic M&A activity has intensified portfolio building-highlighted by Royal Philips' May 2023 acquisition of Vesper Medical (adding advanced deep venous stent technology) and Integer Holdings' December 2021 purchase of Oscor (integrating relevant vascular access and catheter capabilities).

Subscribe for Year-Round Insights → Stay ahead with quarterly and annual data updates:https://www.futuremarketinsights.com/reports/brochure/rep-gb-8023

Get Access of Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-8023

Scope of the Report

Quantitative Units: Value in USD (USD 9.58 billion in 2026 to USD 17.84 billion in 2036 at 6.4% CAGR)
Market Definition: Global supply of interventions and products for managing long-term venous blockages via endovenous ablation, venous stenting, pharmacologic agents, and compression therapies across hospital, ambulatory surgical center, and specialty clinic settings
Treatment Type Segmentation: Endovenous Laser Ablation, Radiofrequency Ablation, Sclerotherapy, Compression Therapy, Others
Product Segmentation: Devices, Drugs
End User Segmentation: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others
Region Segmentation: North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Countries Covered: United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, India, Japan, South Korea, Brazil and 40+ additional countries
Key Companies Profiled: Cardinal Health, Stryker, Boston Scientific Corporation, Edwards Lifesciences, Cook Medical, Medtronic, AngioDynamics, Gore, Bayer AG, Sanofi
Forecast Period: 2026 to 2036
Approach: Hybrid top-down / bottom-up modeling validated via primary interviews with vascular surgeons, interventional radiologists, and procurement managers, plus procedure volume and trade benchmarking

FAQ

What is the projected size of the chronic venous occlusions treatment market in 2036? The market is forecasted to reach USD 17.84 billion by 2036.

What CAGR is expected for the chronic venous occlusions treatment market from 2026 to 2036? A 6.4% CAGR is projected over the 2026-2036 period.

Which treatment type holds the leading share? Endovenous laser ablation accounts for 32.6% of the market.

Which product category dominates? Devices represent 52.9% of the chronic venous occlusions treatment market.

Which end user segment is largest today? Hospitals lead with 45.2% share, although ambulatory surgical centers are expanding most rapidly.

Which countries show the highest growth rates? China leads at 7.2% CAGR, followed by India at 6.8% and Germany at 6.2%.

Explore More Related Studies Published by FMI Research:

Lung Cancer Surgery Market: https://www.futuremarketinsights.com/reports/lung-cancer-surgery-market

Beadlets Capsule Market: https://www.futuremarketinsights.com/reports/beadlets-capsule-market

Demand for Antibody-mediated Rejection Prevention in USA: https://www.futuremarketinsights.com/reports/united-states-antibody-mediated-rejection-prevention-market

Demand for Anti-biofilm Wound Dressing in USA: https://www.futuremarketinsights.com/reports/united-states-anti-biofilm-wound-dressing-market

DKK-1 Biomarker Market: https://www.futuremarketinsights.com/reports/dkk-1-biomarker-market

Why FMI: Decisions that Change Outcomes- https://www.futuremarketinsights.com/why-fmi

Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us - sales@futuremarketinsights.com

Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

About Future Market Insights (FMI)

Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.

This release was published on openPR.